News

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
NIH budget cuts are threatening key medical research programs, shrinking training grants, and leaving young researchers ...
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
Synthetic products posing as kratom mislead and endanger consumers; AKA urges FDA to take decisive action against violative ...
A federal judge has ruled that recent mass layoffs at the US Department of Health and Human Services were likely unlawful and ...
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
Store items in a cool, dry place away from direct sunlight. Place your food supply on high shelves to keep them far from any ...
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for ...
Americans are increasingly demanding that chemicals and toxic food dyes be removed from items they consume, clean with, wear, ...
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
The drug gained a following in some circles for its supposed ability to treat COVID-19 safely, something all major medical ...